A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis
Completed
ACADIA Pharmaceuticals Inc.
Phase 3
2010-07-01
The purpose of this study is to evaluate the safety and efficacy of 40 mg pimavanserin
compared to placebo in patients with Parkinson's disease psychosis (PDP).
Expanded Access of Pimavanserin for Patients With PD Psychosis
Approved for marketing
ACADIA Pharmaceuticals Inc.
1969-12-31
The purpose of this program is to provide patients with PDP access to pimavanserin until the
product receives marketing approval from the FDA and is commercially available.
A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis
Recruiting
Tasly Pharmaceutical Group Co., Ltd
Phase 3
2023-09-27
The purpose of this study is to evaluate the safety and efficacy of 34 mg pimavanserin
compared to placebo in patients with Parkinson's disease psychosis (PDP).
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
